Rupatadine Fumarate | CAS#182349-12-8 | CAS#158876-82-5 | H1-Antihistamine

MedKoo Cat#: 328332 | Name: Rupatadine Fumarate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Rupatadine Fumarate, also known as Rupatadine, is a second-generation H1-antihistamine with dual affinity for histamine H1 and PAF receptors. Rupatadine is indicated for the treatment of allergic rhinitis and urticaria.

Chemical Structure

Rupatadine Fumarate

CAS#182349-12-8 (fumarate)

Theoretical Analysis

MedKoo Cat#: 328332

Name: Rupatadine Fumarate

CAS#: 182349-12-8 (fumarate)

Chemical Formula: C30H30ClN3O4

Exact Mass: 0.0000

Molecular Weight: 532.04

Elemental Analysis: C, 67.73; H, 5.68; Cl, 6.66; N, 7.90; O, 12.03

Price and Availability

Size	Price	Availability
200mg	USD 150.00	2 Weeks
500mg	USD 350.00	2 Weeks
1g	USD 550.00	2 Weeks
2g	USD 950.00	2 Weeks
5g	USD 1,950.00	2 Weeks
10g	USD 3,450.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

182349-12-8 (fumarate) 158876-82-5 (free base)

Synonym

Rupatadine Fumarate; Rupafin; Alergoliber; Rinialer; Pafinur; Rupax; Ralif

IUPAC/Chemical Name

8-chloro-11-(1-((5-methylpyridin-3-yl)methyl)piperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine fumarate

InChi Key

JYBLCDXVHQWMSU-WLHGVMLRSA-N

InChi Code

InChI=1S/C26H26ClN3.C4H4O4/c1-18-13-19(16-28-15-18)17-30-11-8-20(9-12-30)25-24-7-6-23(27)14-22(24)5-4-21-3-2-10-29-26(21)25;5-3(6)1-2-4(7)8/h2-3,6-7,10,13-16H,4-5,8-9,11-12,17H2,1H3;1-2H,(H,5,6)(H,7,8)/b;2-1+

SMILES Code

CC1=CN=CC(CN2CC/C(CC2)=C3C4=CC=C(Cl)C=C4CCC5=CC=CN=C5\3)=C1.O=C(O)/C=C/C(O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Related CAS# 158876-82-5(Rupatadine) 182349-12-8(Rupatadine Fumarate)

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Rupatadine fumarate is a potent, orally active and long-lasting dual PAF/H1 antagonist, with Kis of 0.55 μM and 0.1 μM, respectively.

In vitro activity:

Rupatadine demonstrated significant inhibition of PAF-induced degranulation in both LAD2 and human lung tissue mast cells (hLMCs). This study confirms that rupatadine possesses dual antihistamine and anti-PAF effects, making it a promising option for treating allergic disorders. Reference: J Investig Allergol Clin Immunol. 2017;27(3):161-168. https://pubmed.ncbi.nlm.nih.gov/27758758/

In vivo activity:

Rupatadine enhanced the anti-fibrotic efficacy of mesenchymal stem cell-derived exosomes when used as a combined therapy. This was revealed through attenuation of PAF/RIPK3/MLKL/HMGB1, and TGF-β1/hedgehog signaling pathways with a significant role for miR-200a. Reference: Life Sci. 2023 Jul 1;324:121710. https://pubmed.ncbi.nlm.nih.gov/37084952/

	Solvent	mg/mL	mM
Solubility
	DMF	1.0	1.88
	DMSO	1.0	1.88

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 532.04 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Munoz-Cano R, Ainsua-Enrich E, Torres-Atencio I, Martin M, Sánchez-Lopez J, Bartra J, Picado C, Mullol J, Valero A. Effects of Rupatadine on Platelet- Activating Factor-Induced Human Mast Cell Degranulation Compared With Desloratadine and Levocetirizine (The MASPAF Study). J Investig Allergol Clin Immunol. 2017;27(3):161-168. doi: 10.18176/jiaci.0117. Epub 2016 Oct 19. PMID: 27758758. 2. Alevizos M, Karagkouni A, Vasiadi M, Sismanopoulos N, Makris M, Kalogeromitros D, Theoharides TC. Rupatadine inhibits inflammatory mediator release from human laboratory of allergic diseases 2 cultured mast cells stimulated by platelet-activating factor. Ann Allergy Asthma Immunol. 2013 Dec;111(6):542-7. doi: 10.1016/j.anai.2013.08.025. Epub 2013 Sep 21. PMID: 24267366. 3. Didamoony MA, Atwa AM, Ahmed LA. Modulatory effect of rupatadine on mesenchymal stem cell-derived exosomes in hepatic fibrosis in rats: A potential role for miR-200a. Life Sci. 2023 Jul 1;324:121710. doi: 10.1016/j.lfs.2023.121710. Epub 2023 Apr 19. PMID: 37084952. 4. Ibrahim MA, Abdelmonaem AA, Abdel-Gaber SA, Hafez HM, Abdel Hafez SMN, Yehia Abdelzaher W. Rupatadine ameliorated ulcerative colitis in rats via modulation of platelet-activatiweng factor/interleukin-6/vascular endothelial growth factor signalling pathway. J Pharm Pharmacol. 2022 Apr 20;74(4):537-546. doi: 10.1093/jpp/rgab170. PMID: 35134225.

In vitro protocol:

In vivo protocol:

1. Didamoony MA, Atwa AM, Ahmed LA. Modulatory effect of rupatadine on mesenchymal stem cell-derived exosomes in hepatic fibrosis in rats: A potential role for miR-200a. Life Sci. 2023 Jul 1;324:121710. doi: 10.1016/j.lfs.2023.121710. Epub 2023 Apr 19. PMID: 37084952. 2. Ibrahim MA, Abdelmonaem AA, Abdel-Gaber SA, Hafez HM, Abdel Hafez SMN, Yehia Abdelzaher W. Rupatadine ameliorated ulcerative colitis in rats via modulation of platelet-activatiweng factor/interleukin-6/vascular endothelial growth factor signalling pathway. J Pharm Pharmacol. 2022 Apr 20;74(4):537-546. doi: 10.1093/jpp/rgab170. PMID: 35134225.

1: Lin S, Lou Y, Hao R, Shao Y, Yu J, Fang L, Bao M, Yi W, Zhang Y. A single- dose, randomized, open-label, four-period, crossover equivalence trial comparing the clinical similarity of the proposed biosimilar rupatadine fumarate to reference Wystamm® in healthy Chinese subjects. Front Pharmacol. 2024 May 17;15:1328142. doi: 10.3389/fphar.2024.1328142. PMID: 38828454; PMCID: PMC11140027. 2: Intelligence And Neuroscience C. Retracted: Efficacy and Safety of Rupatadine Fumarate Combined with Acupoint Application in Allergic Rhinitis Complicated with Diabetes. Comput Intell Neurosci. 2023 Dec 13;2023:9803914. doi: 10.1155/2023/9803914. PMID: 38124823; PMCID: PMC10732883. 3: Amer MM, Habib AA, Hammad SF, Kamal AH. Green micellar stability-indicating high-performance liquid chromatography method for determination of rupatadine fumarate in the presence of its main impurity desloratadine: Oxidative degradation kinetics study. J Sep Sci. 2023 Jul;46(14):e2300135. doi: 10.1002/jssc.202300135. Epub 2023 May 26. PMID: 37232201. 4: Olechno K, Grilc NK, Zupančič Š, Winnicka K. Incorporation of Ethylcellulose Microparticles Containing a Model Drug with a Bitter Taste into Nanofibrous Mats by the Electrospinning Technique-Preliminary Studies. Materials (Basel). 2022 Jul 31;15(15):5286. doi: 10.3390/ma15155286. PMID: 35955221; PMCID: PMC9369697. 5: Liu Y, Jiang P, Chen X, Zhang W, Shi J. Efficacy and Safety of Rupatadine Fumarate Combined with Acupoint Application in Allergic Rhinitis Complicated with Diabetes. Comput Intell Neurosci. 2022 Jun 14;2022:6935758. doi: 10.1155/2022/6935758. Retraction in: Comput Intell Neurosci. 2023 Dec 13;2023:9803914. doi: 10.1155/2023/9803914. PMID: 35747720; PMCID: PMC9213154. 6: Olechno K, Maciejewski B, Głowacz K, Lenik J, Ciosek-Skibińska P, Basa A, Winnicka K. Orodispersible Films with Rupatadine Fumarate Enclosed in Ethylcellulose Microparticles as Drug Delivery Platform with Taste-Masking Effect. Materials (Basel). 2022 Mar 14;15(6):2126. doi: 10.3390/ma15062126. PMID: 35329589; PMCID: PMC8952792. 7: Won TB, Kim HG, Kim JW, Kim JK, Kim YH, Kim SW, Kim HY, Kim DW, Kim SW, Kim CH, Rhee CS. Efficacy and safety of rupatadine fumarate in the treatment of perennial allergic rhinitis: A multicenter, double-blinded, randomized, placebo- controlled, bridging study in Koreans. Asian Pac J Allergy Immunol. 2021 Jul 11. doi: 10.12932/AP-201220-1019. Epub ahead of print. PMID: 34246214. 8: Kahveci OK, Kuzu S, Altıntaş M, Vurmaz A, Çelik S. The Effect of Nasal Steroid and Antihistamine Use on Total Oxidative Stress and Antioxidant Status in the Treatment of Allergic Rhinitis. Am J Rhinol Allergy. 2021 Jan;35(1):52-58. doi: 10.1177/1945892420932768. Epub 2020 Jun 19. PMID: 32551922. 9: Wasilewska K, Ciosek-Skibińska P, Lenik J, Srčič S, Basa A, Winnicka K. Utilization of Ethylcellulose Microparticles with Rupatadine Fumarate in Designing Orodispersible Minitablets with Taste Masking Effect. Materials (Basel). 2020 Jun 15;13(12):2715. doi: 10.3390/ma13122715. PMID: 32549213; PMCID: PMC7344686. 10: Castillo Henríquez L, Vargas Zúñiga R, Carazo Berrocal G, Madrigal Redondo G, Calvo Guzmán B, Baltodano Viales E. Development of immediate release Rupatadine fumarate 10 mg tablets: A Quality by Design (QbD) approach. Drug Dev Ind Pharm. 2019 Oct;45(10):1674-1681. doi: 10.1080/03639045.2019.1652637. Epub 2019 Aug 30. PMID: 31378098. 11: Wasilewska K, Szekalska M, Ciosek-Skibinska P, Lenik J, Basa A, Jacyna J, Markuszewski M, Winnicka K. Ethylcellulose in Organic Solution or Aqueous Dispersion Form in Designing Taste-Masked Microparticles by the Spray Drying Technique with a Model Bitter Drug: Rupatadine Fumarate. Polymers (Basel). 2019 Mar 20;11(3):522. doi: 10.3390/polym11030522. PMID: 30960506; PMCID: PMC6473340. 12: Sun C, Li Q, Pan L, Liu B, Gu P, Zhang J, Ding L, Wu C. Development of a highly sensitive LC-MS/MS method for simultaneous determination of rupatadine and its two active metabolites in human plasma: Application to a clinical pharmacokinetic study. J Pharm Biomed Anal. 2015;111:163-8. doi: 10.1016/j.jpba.2015.03.025. Epub 2015 Apr 3. PMID: 25890211. 13: Molyva D, Kalokasidis K, Poulios C, Dedi H, Karkavelas G, Mirtsou V, Goulas A. Rupatadine effectively prevents the histamine-induced up regulation of histamine H1R and bradykinin B2R receptor gene expression in the rat paw. Pharmacol Rep. 2014 Dec;66(6):952-5. doi: 10.1016/j.pharep.2014.06.008. Epub 2014 Jun 21. PMID: 25443720. 14: Souto RB, Stamm FP, Schumacher JB, Cardoso CD Jr, de Freitas GW, Perobelli RF, Dalmora SL. Stability-indicating capillary zone electrophoresis method for the assessment of recombinant human interleukin-11 and its correlation with reversed-phase liquid chromatography and biossay. Talanta. 2014 Jun;123:179-85. doi: 10.1016/j.talanta.2014.01.065. Epub 2014 Feb 20. PMID: 24725881. 15: Nettis E, Delle Donne P, Di Leo E, Calogiuri GF, Ferrannini A, Vacca A. Rupatadine for the treatment of urticaria. Expert Opin Pharmacother. 2013 Sep;14(13):1807-13. doi: 10.1517/14656566.2013.813481. Epub 2013 Jun 28. PMID: 23806068. 16: Maiti R, Jaida J, Rahman J, Gaddam R, Palani A. Olopatadine hydrochloride and rupatadine fumarate in seasonal allergic rhinitis: A comparative study of efficacy and safety. J Pharmacol Pharmacother. 2011 Oct;2(4):270-6. doi: 10.4103/0976-500X.85958. PMID: 22025856; PMCID: PMC3198523. 17: Fidan V, Fidan T. Fixed drug eruption against rupatadine fumarate. J Craniofac Surg. 2011 Sep;22(5):1682-3. doi: 10.1097/SCS.0b013e31822e5c76. PMID: 21959412. 18: Maiti R, Rahman J, Jaida J, Allala U, Palani A. Rupatadine and levocetirizine for seasonal allergic rhinitis: a comparative study of efficacy and safety. Arch Otolaryngol Head Neck Surg. 2010 Aug;136(8):796-800. doi: 10.1001/archoto.2010.128. PMID: 20713756. 19: Mion Ode G, Campos RA, Antila M, Rapoport PB, Rosario N, de Mello Junior JF, Guimarães RE, Mocellin M, Di Gesu G, Solé D, Wexler L, de Mello JF, Castro FM, Chavarria ML. Futura study: evaluation of efficacy and safety of rupatadine fumarate in the treatment of persistent allergic rhinitis. Braz J Otorhinolaryngol. 2009 Sep-Oct;75(5):673-9. doi: 10.1590/s1808-86942009000500011. PMID: 19893935; PMCID: PMC9442186. 20: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Nov;29(9):625-55. PMID: 18193114.